Development of New Antibacterials: A Laudable Aim, But What Is the Value?

被引:4
作者
Tillotson, Glenn S. [1 ]
机构
[1] ViroPharma Inc, Exton, PA 19431 USA
关键词
DRUGS;
D O I
10.1086/655956
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
收藏
页码:752 / 753
页数:3
相关论文
共 4 条
[1]   A Comparative Study on the Cost of New Antibiotics and Drugs of Other Therapeutic Categories [J].
Falagas, Matthew E. ;
Fragoulis, Konstantinos N. ;
Karydis, Ioannis .
PLOS ONE, 2006, 1 (01)
[2]   The 10 x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020 [J].
Gilbert, David N. ;
Guidos, Robert J. ;
Boucher, Helen W. ;
Talbot, George H. ;
Spellberg, Brad ;
Edwards, John E., Jr. ;
Scheld, W. Michael ;
Bradley, John S. ;
Bartlett, John G. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (08) :1081-1083
[3]  
Spellberg B., 2009, Rising Plague: the Global Threat from Deadly Bacteria and Our Dwindling Arsenal to Fight Them
[4]   Stimulating antibiotic development [J].
Tillotson, Glenn .
LANCET INFECTIOUS DISEASES, 2010, 10 (01) :2-3